SIS
VKTX icon

Sound Income Strategies’s Viking Therapeutics VKTX Stock Holding History

Sound Income Strategies’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-385
Closed -$12.7K – 2334
2026
Q1 		$12.7K Buy
385
+160
+71% +$5.14K ﹤0.01% 1396
2025
Q4 		$7.63K Sell
225
-39
-15% -$1.38K ﹤0.01% 1612
2025
Q3 		$9.23K Buy
+264
New +$7.88K ﹤0.01% 1037

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sound Income Strategies's VKTX Position: Q2 2026 in Review

Sound Income Strategies sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 385 shares — an estimated $12.7K sold.

Sound Income Strategies first reported a position in VKTX in Q3 2025 and held it in 3 quarters. The position peaked at $12.7K in Q1 2026. 316 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Sound Income Strategies reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 385 Viking Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Sound Income Strategies first reported a position in Viking Therapeutics in Q3 2025 and held it in 3 quarters.
  • Sound Income Strategies's Viking Therapeutics position peaked at $12.7K in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.